

NOTICE TO THE BAR

**RE: APPLICATION FOR MASS TORT DESIGNATION AND CENTRALIZED
MANAGEMENT OF NUVARING® LITIGATION**

A previous notice requested comments on the application made for centralized management, but not mass tort designation, of all litigation involving the contraceptive NuvaRing® in a designated North Jersey Mass Tort site. In response to that Notice, and pursuant to *Rule 4:38A* and Administrative Directive #10-07, “Mass Torts – Revised Guidelines and Criteria for Designation,” another application has been made to the Supreme Court, through the Acting Administrative Director of the Courts, for mass tort designation of all NuvaRing® litigation and centralized management of that litigation in one of the designated mass tort sites.

Anyone wishing to comment on or object to this second application regarding NuvaRing® litigation should provide such comments or objections, with relevant supporting documentation, to Glenn A. Grant, J.A.D., Acting Administrative Director of the Courts, P.O. Box 037, Trenton, NJ 08625-0037, **by February 15, 2009**.

Thereafter the Supreme Court will consider both applications and any comments received, and will make a determination as to the appropriate designation of the litigation and, if it is to be centrally managed, the county to which it will be assigned.

/s/ Glenn A. Grant

Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: December 16, 2008